Preclinical evaluation of triple-mutated oncolytic herpes virus expressing fusion-type interleukin 12 for malignant melanoma
Miwako Iwai, Akiko Higuchi Nonaka, Minoru Tanaka, Hiroshi Fukuhara, Tomoki Todo · 2026
Read Preclinical evaluation of triple-mutated oncolytic herpes virus expressing fusion-type interleukin 12 for malignant melanoma by Miwako Iwai, Akiko Higuchi Nonaka, Minoru Tanaka, Hiroshi Fukuhara, Tomoki Todo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13597883.txt.
Description
Iwai, Higuchi Nonaka, Tanaka, Fukuhara, and Todo evaluate an engineered oncolytic herpes virus for malignant melanoma, in a preclinical study from twenty twenty-six. A triple-mutated virus already approved for brain tumors kills cancer selectively. Their version also produces a fusion form of interleukin twelve. Mouse melanoma and safety models test the construct.
Injected tumors shrink, and immune genes rise even in distant tumors. Adding PD-one blockade strengthens the effect further. Brain and skin safety tests in sensitive mice show no major harm. Virus DNA stays confined to the injection site. A phase one-two human trial is now underway.
Catalog record
| CREATOR | Miwako Iwai, Akiko Higuchi Nonaka, Minoru Tanaka, Hiroshi Fukuhara, Tomoki Todo |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |